Olivia Newton-John Cancer Research Institute   Report issue

Academic/Hospital Phase 1 Phase 2
Founded: Heidelberg Australia (2014)

Organization Overview

First Clinical Trial
2016
NCT02824965
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Olivia Newton-John Cancer Research Institute | Olivia Newton-John Cancer Wellness and Research Centre

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Colorectal Neoplasms (Phase 2)

Gastrointestinal Neoplasms (Phase 2)

Genital Neoplasms, Female (Phase 2)

Glioblastoma (Phase 1)

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 1)

Lymphoma, Follicular (Phase 1)

Lymphoma, Large B-Cell, Diffuse (Phase 1)

Neuroendocrine Tumors (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 11
  • # of Trial APIs: 18